Oramed Pharmaceuticals (ORMP) Competitors

$3.98 +0.05 (+1.17%)

Closing price 03:59 PM Eastern

Extended Trading

$3.98 +0.01 (+0.23%)

As of 04:10 PM Eastern

ORMP vs. PRME, ARVN, ETON, CRMD, and ACRS

Should you be buying Oramed Pharmaceuticals stock or one of its competitors? The main competitors of Oramed Pharmaceuticals include Prime Medicine (PRME), Arvinas (ARVN), Eton Pharmaceuticals (ETON), CorMedix (CRMD), and Aclaris Therapeutics (ACRS). These companies are all part of the "pharmaceutical products" industry.

How does Oramed Pharmaceuticals compare to Prime Medicine?

Oramed Pharmaceuticals (NASDAQ:ORMP) and Prime Medicine (NASDAQ:PRME) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, media sentiment, valuation, profitability and analyst recommendations.

: In the previous week, Prime Medicine had 2 more articles in the media than Oramed Pharmaceuticals. MarketBeat recorded 2 mentions for Prime Medicine and 0 mentions for Oramed Pharmaceuticals. Prime Medicine's average media sentiment score of 1.22 beat Oramed Pharmaceuticals' score of 0.00 indicating that Prime Medicine is being referred to more favorably in the news media.
Company Overall Sentiment
Oramed Pharmaceuticals Neutral
Prime Medicine Positive
: Oramed Pharmaceuticals has higher earnings, but lower revenue than Prime Medicine. Prime Medicine is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Oramed Pharmaceuticals $2M 80.41 $64.05M $1.49 2.67
Prime Medicine $4.63M 132.44 -$201.14M -$1.35 N/A
: 12.7% of Oramed Pharmaceuticals shares are held by institutional investors. Comparatively, 70.4% of Prime Medicine shares are held by institutional investors. 17.8% of Oramed Pharmaceuticals shares are held by company insiders. Comparatively, 22.7% of Prime Medicine shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
: Prime Medicine has a consensus target price of $7.38, suggesting a potential upside of 117.23%. Given Prime Medicine's stronger consensus rating and higher probable upside, analysts clearly believe Prime Medicine is more favorable than Oramed Pharmaceuticals.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oramed Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
2.00
Prime Medicine
1 Sell rating(s)

3 Hold rating(s)

4 Buy rating(s)

1 Strong Buy rating(s)
2.56
: Oramed Pharmaceuticals has a net margin of 0.00% compared to Prime Medicine's net margin of -4,342.44%. Oramed Pharmaceuticals' return on equity of -6.83% beat Prime Medicine's return on equity.
Company Net Margins Return on Equity Return on Assets
Oramed Pharmaceuticals N/A -6.83% -6.25%
Prime Medicine -4,342.44% -178.60% -60.27%
: Oramed Pharmaceuticals has a beta of 1.27, indicating that its share price is 27% more volatile than the S&P 500. Comparatively, Prime Medicine has a beta of 2.35, indicating that its share price is 135% more volatile than the S&P 500.

Company	Overall Sentiment
Oramed Pharmaceuticals	Neutral
Prime Medicine	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oramed Pharmaceuticals	$2M	80.41	$64.05M	$1.49	2.67
Prime Medicine	$4.63M	132.44	-$201.14M	-$1.35	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oramed Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Prime Medicine	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56

Company	Net Margins	Return on Equity	Return on Assets
Oramed Pharmaceuticals	N/A	-6.83%	-6.25%
Prime Medicine	-4,342.44%	-178.60%	-60.27%

Summary

Prime Medicine beats Oramed Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Oramed Pharmaceuticals compare to Arvinas?

Oramed Pharmaceuticals (NASDAQ:ORMP) and Arvinas (NASDAQ:ARVN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

: In the previous week, Arvinas had 12 more articles in the media than Oramed Pharmaceuticals. MarketBeat recorded 12 mentions for Arvinas and 0 mentions for Oramed Pharmaceuticals. Arvinas' average media sentiment score of 0.40 beat Oramed Pharmaceuticals' score of 0.00 indicating that Arvinas is being referred to more favorably in the news media.
Company Overall Sentiment
Oramed Pharmaceuticals Neutral
Arvinas Neutral
: Oramed Pharmaceuticals has higher earnings, but lower revenue than Arvinas. Arvinas is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Oramed Pharmaceuticals $2M 80.41 $64.05M $1.49 2.67
Arvinas $262.60M 2.58 -$80.80M -$1.28 N/A
: 12.7% of Oramed Pharmaceuticals shares are held by institutional investors. Comparatively, 95.2% of Arvinas shares are held by institutional investors. 17.8% of Oramed Pharmaceuticals shares are held by insiders. Comparatively, 4.7% of Arvinas shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
: Arvinas has a consensus target price of $14.60, suggesting a potential upside of 37.64%. Given Arvinas' stronger consensus rating and higher possible upside, analysts clearly believe Arvinas is more favorable than Oramed Pharmaceuticals.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oramed Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
2.00
Arvinas
3 Sell rating(s)

4 Hold rating(s)

9 Buy rating(s)

0 Strong Buy rating(s)
2.38
: Oramed Pharmaceuticals has a net margin of 0.00% compared to Arvinas' net margin of -30.77%. Oramed Pharmaceuticals' return on equity of -6.83% beat Arvinas' return on equity.
Company Net Margins Return on Equity Return on Assets
Oramed Pharmaceuticals N/A -6.83% -6.25%
Arvinas -30.77% -14.25% -9.31%
: Oramed Pharmaceuticals has a beta of 1.27, indicating that its stock price is 27% more volatile than the S&P 500. Comparatively, Arvinas has a beta of 1.79, indicating that its stock price is 79% more volatile than the S&P 500.

Company	Overall Sentiment
Oramed Pharmaceuticals	Neutral
Arvinas	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oramed Pharmaceuticals	$2M	80.41	$64.05M	$1.49	2.67
Arvinas	$262.60M	2.58	-$80.80M	-$1.28	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oramed Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Arvinas	3 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.38

Company	Net Margins	Return on Equity	Return on Assets
Oramed Pharmaceuticals	N/A	-6.83%	-6.25%
Arvinas	-30.77%	-14.25%	-9.31%

Summary

Oramed Pharmaceuticals and Arvinas tied by winning 8 of the 16 factors compared between the two stocks.

How does Oramed Pharmaceuticals compare to Eton Pharmaceuticals?

Eton Pharmaceuticals (NASDAQ:ETON) and Oramed Pharmaceuticals (NASDAQ:ORMP) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, earnings, valuation, media sentiment, dividends and analyst recommendations.

: Eton Pharmaceuticals currently has a consensus target price of $39.33, suggesting a potential upside of 29.54%. Given Eton Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Eton Pharmaceuticals is more favorable than Oramed Pharmaceuticals.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Eton Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)

3 Buy rating(s)

0 Strong Buy rating(s)
2.40
Oramed Pharmaceuticals
0 Sell rating(s)

1 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
2.00
: Oramed Pharmaceuticals has a net margin of 0.00% compared to Eton Pharmaceuticals' net margin of -5.75%. Eton Pharmaceuticals' return on equity of -2.60% beat Oramed Pharmaceuticals' return on equity.
Company Net Margins Return on Equity Return on Assets
Eton Pharmaceuticals -5.75% -2.60% -0.66%
Oramed Pharmaceuticals N/A -6.83% -6.25%
: 27.9% of Eton Pharmaceuticals shares are owned by institutional investors. Comparatively, 12.7% of Oramed Pharmaceuticals shares are owned by institutional investors. 16.0% of Eton Pharmaceuticals shares are owned by insiders. Comparatively, 17.8% of Oramed Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
: Oramed Pharmaceuticals has lower revenue, but higher earnings than Eton Pharmaceuticals. Eton Pharmaceuticals is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Eton Pharmaceuticals $79.95M 10.39 -$4.60M -$0.18 N/A
Oramed Pharmaceuticals $2M 80.41 $64.05M $1.49 2.67
: In the previous week, Eton Pharmaceuticals had 11 more articles in the media than Oramed Pharmaceuticals. MarketBeat recorded 11 mentions for Eton Pharmaceuticals and 0 mentions for Oramed Pharmaceuticals. Eton Pharmaceuticals' average media sentiment score of 0.55 beat Oramed Pharmaceuticals' score of 0.00 indicating that Eton Pharmaceuticals is being referred to more favorably in the media.
Company Overall Sentiment
Eton Pharmaceuticals Positive
Oramed Pharmaceuticals Neutral
: Eton Pharmaceuticals has a beta of 0.82, meaning that its share price is 18% less volatile than the S&P 500. Comparatively, Oramed Pharmaceuticals has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eton Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Oramed Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Net Margins	Return on Equity	Return on Assets
Eton Pharmaceuticals	-5.75%	-2.60%	-0.66%
Oramed Pharmaceuticals	N/A	-6.83%	-6.25%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eton Pharmaceuticals	$79.95M	10.39	-$4.60M	-$0.18	N/A
Oramed Pharmaceuticals	$2M	80.41	$64.05M	$1.49	2.67

Company	Overall Sentiment
Eton Pharmaceuticals	Positive
Oramed Pharmaceuticals	Neutral

Summary

Eton Pharmaceuticals beats Oramed Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Oramed Pharmaceuticals compare to CorMedix?

CorMedix (NASDAQ:CRMD) and Oramed Pharmaceuticals (NASDAQ:ORMP) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, earnings, valuation, media sentiment, dividends and analyst recommendations.

: CorMedix has higher revenue and earnings than Oramed Pharmaceuticals. Oramed Pharmaceuticals is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
CorMedix $311.71M 1.94 $163.05M $2.00 3.86
Oramed Pharmaceuticals $2M 80.41 $64.05M $1.49 2.67
: In the previous week, CorMedix had 3 more articles in the media than Oramed Pharmaceuticals. MarketBeat recorded 3 mentions for CorMedix and 0 mentions for Oramed Pharmaceuticals. CorMedix's average media sentiment score of 0.67 beat Oramed Pharmaceuticals' score of 0.00 indicating that CorMedix is being referred to more favorably in the media.
Company Overall Sentiment
CorMedix Positive
Oramed Pharmaceuticals Neutral
: 34.2% of CorMedix shares are owned by institutional investors. Comparatively, 12.7% of Oramed Pharmaceuticals shares are owned by institutional investors. 3.1% of CorMedix shares are owned by insiders. Comparatively, 17.8% of Oramed Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
: CorMedix has a net margin of 52.31% compared to Oramed Pharmaceuticals' net margin of 0.00%. CorMedix's return on equity of 52.30% beat Oramed Pharmaceuticals' return on equity.
Company Net Margins Return on Equity Return on Assets
CorMedix 52.31% 52.30% 29.46%
Oramed Pharmaceuticals N/A -6.83% -6.25%
: CorMedix currently has a consensus target price of $15.00, suggesting a potential upside of 94.12%. Given CorMedix's stronger consensus rating and higher possible upside, equities analysts clearly believe CorMedix is more favorable than Oramed Pharmaceuticals.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CorMedix
1 Sell rating(s)
1 Hold rating(s)

6 Buy rating(s)

0 Strong Buy rating(s)
2.63
Oramed Pharmaceuticals
0 Sell rating(s)

1 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
2.00
: CorMedix has a beta of 1.46, meaning that its share price is 46% more volatile than the S&P 500. Comparatively, Oramed Pharmaceuticals has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CorMedix	$311.71M	1.94	$163.05M	$2.00	3.86
Oramed Pharmaceuticals	$2M	80.41	$64.05M	$1.49	2.67

Company	Overall Sentiment
CorMedix	Positive
Oramed Pharmaceuticals	Neutral

Company	Net Margins	Return on Equity	Return on Assets
CorMedix	52.31%	52.30%	29.46%
Oramed Pharmaceuticals	N/A	-6.83%	-6.25%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CorMedix	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Oramed Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

CorMedix beats Oramed Pharmaceuticals on 14 of the 16 factors compared between the two stocks.

How does Oramed Pharmaceuticals compare to Aclaris Therapeutics?

Aclaris Therapeutics (NASDAQ:ACRS) and Oramed Pharmaceuticals (NASDAQ:ORMP) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings, media sentiment and analyst recommendations.

: Oramed Pharmaceuticals has lower revenue, but higher earnings than Aclaris Therapeutics. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Aclaris Therapeutics $7.83M 84.93 -$64.92M -$0.53 N/A
Oramed Pharmaceuticals $2M 80.41 $64.05M $1.49 2.67
: In the previous week, Aclaris Therapeutics had 2 more articles in the media than Oramed Pharmaceuticals. MarketBeat recorded 2 mentions for Aclaris Therapeutics and 0 mentions for Oramed Pharmaceuticals. Aclaris Therapeutics' average media sentiment score of 0.76 beat Oramed Pharmaceuticals' score of 0.00 indicating that Aclaris Therapeutics is being referred to more favorably in the media.
Company Overall Sentiment
Aclaris Therapeutics Positive
Oramed Pharmaceuticals Neutral
: 98.3% of Aclaris Therapeutics shares are owned by institutional investors. Comparatively, 12.7% of Oramed Pharmaceuticals shares are owned by institutional investors. 5.6% of Aclaris Therapeutics shares are owned by company insiders. Comparatively, 17.8% of Oramed Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
: Oramed Pharmaceuticals has a net margin of 0.00% compared to Aclaris Therapeutics' net margin of -829.58%. Oramed Pharmaceuticals' return on equity of -6.83% beat Aclaris Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Aclaris Therapeutics -829.58% -52.04% -35.91%
Oramed Pharmaceuticals N/A -6.83% -6.25%
: Aclaris Therapeutics currently has a consensus price target of $11.00, suggesting a potential upside of 131.14%. Given Aclaris Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Aclaris Therapeutics is more favorable than Oramed Pharmaceuticals.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aclaris Therapeutics
1 Sell rating(s)
0 Hold rating(s)

6 Buy rating(s)

1 Strong Buy rating(s)
2.88
Oramed Pharmaceuticals
0 Sell rating(s)

1 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
2.00
: Aclaris Therapeutics has a beta of 0.76, indicating that its stock price is 24% less volatile than the S&P 500. Comparatively, Oramed Pharmaceuticals has a beta of 1.27, indicating that its stock price is 27% more volatile than the S&P 500.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclaris Therapeutics	$7.83M	84.93	-$64.92M	-$0.53	N/A
Oramed Pharmaceuticals	$2M	80.41	$64.05M	$1.49	2.67

Company	Overall Sentiment
Aclaris Therapeutics	Positive
Oramed Pharmaceuticals	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Aclaris Therapeutics	-829.58%	-52.04%	-35.91%
Oramed Pharmaceuticals	N/A	-6.83%	-6.25%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Oramed Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Aclaris Therapeutics beats Oramed Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

Get Oramed Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ORMP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ORMP vs. The Competition

Export

Metric	Oramed Pharmaceuticals	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$160.81M	$8.15B	$6.25B	$11.87B
Dividend Yield	6.44%	2.45%	2.73%	5.21%
P/E Ratio	2.67	119.46	29.03	28.47
Price / Sales	80.41	7.43	476.10	60.92
Price / Cash	43.87	17.32	27.62	36.52
Price / Book	0.79	3.53	9.67	6.67
Net Income	$64.05M	$223.69M	$3.55B	$332.53M
7 Day Performance	-1.34%	0.07%	1.75%	2.03%
1 Month Performance	16.26%	10.16%	5.66%	9.23%
1 Year Performance	72.12%	0.93%	34.42%	39.62%

Oramed Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ORMP Oramed Pharmaceuticals	1.405 of 5 stars	$3.98 +1.2%	N/A	N/A	$160.81M	$2M	2.67	10
PRME Prime Medicine	2.1785 of 5 stars	$3.69 +0.5%	$7.38 +99.9%	N/A	$662.86M	$4.63M	N/A	N/A	Positive News Analyst Upgrade
ARVN Arvinas	3.1754 of 5 stars	$10.22 -0.7%	$13.88 +35.8%	N/A	$658.16M	$262.60M	N/A	420	News Coverage Upcoming Earnings Analyst Forecast
ETON Eton Pharmaceuticals	3.9497 of 5 stars	$24.16 +3.0%	$39.33 +62.8%	N/A	$641.59M	$79.95M	N/A	20	News Coverage Upcoming Earnings
CRMD CorMedix	3.3741 of 5 stars	$7.57 -3.2%	$15.00 +98.2%	N/A	$618.17M	$311.71M	3.79	30	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ORMP) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Oramed Pharmaceuticals (ORMP) Competitors

ORMP vs. PRME, ARVN, ETON, CRMD, and ACRS

How does Oramed Pharmaceuticals compare to Prime Medicine?

Summary

How does Oramed Pharmaceuticals compare to Arvinas?

Summary

How does Oramed Pharmaceuticals compare to Eton Pharmaceuticals?

Summary

How does Oramed Pharmaceuticals compare to CorMedix?

Summary

How does Oramed Pharmaceuticals compare to Aclaris Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORMP vs. The Competition

Oramed Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Oramed Pharmaceuticals (ORMP) Competitors

ORMP vs. PRME, ARVN, ETON, CRMD, and ACRS

How does Oramed Pharmaceuticals compare to Prime Medicine?

Summary

How does Oramed Pharmaceuticals compare to Arvinas?

Summary

How does Oramed Pharmaceuticals compare to Eton Pharmaceuticals?

Summary

How does Oramed Pharmaceuticals compare to CorMedix?

Summary

How does Oramed Pharmaceuticals compare to Aclaris Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORMP vs. The Competition

Oramed Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools